Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Suivi à long terme du cabotégravir à action prolongée (CAB LA) pour la PrEP (prophylaxie pré-exposition) chez les participants à risque de contracter le VIH (virus de l'immunodéficience humaine) (PALISADE)

4 novembre 2026 mis à jour par: ViiV Healthcare

Une phase IIIB, suivi à long terme du CAB LA pour les participants aux études HPTN 083 et HPTN 084 CAB PrEP à risque d'acquisition du VIH

The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

2998

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Cape Town, Afrique du Sud, 7505
        • GSK Investigational Site
      • City of Cape Town, Afrique du Sud, 755
        • GSK Investigational Site
      • City of Cape Town, Afrique du Sud, 792
        • GSK Investigational Site
      • City of Johannesburg, Afrique du Sud, 2001
        • GSK Investigational Site
      • Durban, Afrique du Sud, 4110
        • GSK Investigational Site
      • Durban, Afrique du Sud, 4400
        • GSK Investigational Site
      • Isipingo, Afrique du Sud, 4110
        • GSK Investigational Site
      • Sol Plaatjie, Afrique du Sud, 8301
        • GSK Investigational Site
      • Almagro, Argentine, C1427CEA
        • GSK Investigational Site
      • Buenos Aires, Argentine, 1221
        • GSK Investigational Site
      • Francistown, Bostwana
        • GSK Investigational Site
      • Rio de Janeiro, Brésil, 21040-360
        • GSK Investigational Site
      • São Paulo, Brésil, 05403-000
        • GSK Investigational Site
      • São Paulo, Brésil, 04121-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 91350-200
        • GSK Investigational Site
      • Mbabane, Eswatini, H103
        • GSK Investigational Site
      • Kisumu, Kenya, 40100
        • GSK Investigational Site
      • Blantyre, Malawi
        • GSK Investigational Site
      • Lilongwe, Malawi, CLW
        • GSK Investigational Site
      • Entebbe, Ouganda, 49
        • GSK Investigational Site
      • Kampala, Ouganda
        • GSK Investigational Site
      • Lima, Pérou, 15001
        • GSK Investigational Site
      • Lima, Pérou, 15024
        • GSK Investigational Site
      • Lima, Pérou, 15088
        • GSK Investigational Site
      • Lima, Pérou, Lima 04
        • GSK Investigational Site
      • Piura, Pérou, 20000
        • GSK Investigational Site
      • Pathum Wan, Thaïlande, 10330
        • GSK Investigational Site
    • Chiang Mai
      • Chiang Mai, Chiang Mai, Thaïlande, 50200
        • GSK Investigational Site
      • Hanoi, Viêt Nam
        • GSK Investigational Site
      • Chitungwiza, Zimbabwe, 00263
        • GSK Investigational Site
      • Chitungwiza, Zimbabwe, 230221
        • GSK Investigational Site
      • Chitungwiza, Zimbabwe, 263
        • GSK Investigational Site
      • Harare, Zimbabwe
        • GSK Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

Type of participant

  1. Participants must have recently completed or be currently enrolled and ongoing in one of the following studies on the CAB LA arm:

    • HPTN 083 open label extension
    • HPTN 084 open label extension (including pregnancy sub-study)

    Participants that completed study participation ≥3 months ago must be discussed with the Medical Monitor prior to enrolment.

    Participants who have prematurely withdrawn from prior CAB PrEP studies cannot enroll into this study.

  2. Evidence of continued benefit (HIV negative and at risk) from CAB LA during participation in the parent study/sub-study.

  3. Participants must have nonreactive HIV tests at Screening (rapid test, immunoassay [antigen/antibody] test and HIV-1 RNA results must all be available and nonreactive) and Day 1 (at least one of rapid test and immunoassay [antigen/antibody test] results must be available and nonreactive). Participants who have one or more reactive or positive HIV test result(s) will not be enrolled, even if subsequent confirmatory testing indicates they are not HIV-infected.

    Sex

  4. Males and Females:

    All participants who are engaging in sexual activity should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of acquiring HIV and other STIs.

    Females:

    Cisgender female participants who are of childbearing potential and who are engaging in sexual activity that could lead to pregnancy, must talk to the investigator about recommended contraception options. Contraception will be optional in this study. Condoms are recommended in addition, because their appropriate use is the only contraception method effective for preventing HIV-1 transmission.

    Pregnant participants from the HPTN 084 study are eligible to enroll into this study if they meet all eligibility criteria.

    Informed consent

  5. Participant or caregiver/legal guardian is able and willing to provide signed informed consent as described in Protocol Section 11.1.5, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. Where applicable, participants must provide written assent.

Exclusion Criteria:

Concurrent conditions/medical history (includes liver function)

  1. Participants who are currently enrolled in the eligible studies on the TDF/FTC arm are not eligible to enroll into this study. Participants receiving short-term oral TDF/FTC bridging may be enrolled following consultation with the Medical Monitor.

  2. Previous premature discontinuation from IP in the parent study/sub-study.

  3. ALT >5 × ULN; or ALT>3 × ULN and bilirubin >1.5 × ULN (with >35% direct bilirubin) in the screening liver chemistry test result.

  4. Participants with known active hepatitis B infection (as indicated by a positive HBsAg and/or quantifiable HBV DNA). Participants negative for HBsAg but positive for anti-HBc and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded.

  5. Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of hyperbilirubinemia or jaundice due to Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator).

  6. Known history of cirrhosis with or without viral hepatitis co-infection.

  7. Participant is currently participating in or has participated in a study (other than the studies listed in Inclusion Criteria 1) with a compound or device that is not commercially available within 30 days prior to signing informed consent, unless permission from the Medical Monitor is granted.

  8. Presence of or any history of allergy/sensitivity to the study drug or its components.

  9. Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the investigator. Mild skin conditions may not be exclusionary at the discretion of the investigator or designee.

  10. Participant has a gluteal implant, tattoo or other dermatological condition overlying the buttock region which in the opinion of the investigator or designee may interfere with the injection or interpretation of ISRs.

  11. Coagulopathy (primary or iatrogenic) which would contraindicate IM injection. Concomitant medications

  12. Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication.

  13. Anticipated need for HCV therapy with interferon or any drugs that have potential for adverse drug: drug interactions with study treatment throughout the entire study period.

    Relevant habits

  14. Participant is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.

  15. Any condition (i(including but not limited to substance use disorder) that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

    Other

  16. Participant has in the last 14 days prior to screening presented with signs and symptoms, which, in the opinion of the investigator, are suggestive of acute HIV infection. Participants may only be enrolled if clinical suspicion of HIV is ruled out with non-reactive results using appropriate HIV tests as per Inclusion Criterion #3.

  17. Participant is a ward of the state (e.g. child in care).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: CAB LA 600 mg (Q8W)

All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection.

Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).

Autres noms:
  • Appétence
  • CAB LA pour la PrEP

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Nombre de participants avec une nouvelle infection par le VIH
Délai: Du premier jour jusqu'à la fin des études (jusqu'à environ [environ] 3 ans)
Du premier jour jusqu'à la fin des études (jusqu'à environ [environ] 3 ans)
Number of participants with new HIV infection by characteristic
Délai: From Day 1 up to end of study (up to approx. 3 years)

Relevant characteristics of new HIV infections will be assessed, including presence of viral resistance to CAB.

From Day 1 up to end of study (up to approx. 3 years)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of participants with serious adverse events (SAE) by severity
Délai: From Day 1 up to end of study (up to approx. 3 years)

The severity scale is assessed as following: Grade 1 = mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated. Grade 2 = moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated. Grade 3 = severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated. Grade 4 = potentially life-threatening symptoms causing inability to perform self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.

From Day 1 up to end of study (up to approx. 3 years)
Number of participants with Grade 3 and Grade 4 injection site reactions (ISRs)
Délai: From Day 1 up to end of study (up to approx. 3 years)

ISRs may occur following intramuscular administration of CAB LA. Grade 3 refers to severe symptoms causing inability to perform usual social & functional activities with intervention or hospitalization indicated. Grade 4 refers to potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death.

From Day 1 up to end of study (up to approx. 3 years)
Number of participants with any clinical or laboratory AE leading to discontinuation of CAB LA, by severity
Délai: From Day 1 up to end of study (up to approx. 3 years)

Any clinical or laboratory AE that leads the participant to permanently discontinue CAB LA will be assessed. The severity scale is assessed as following: Grade 1 = mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated. Grade 2 = moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated. Grade 3 = severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated. Grade 4 = potentially life-threatening symptoms causing inability to perform self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.

From Day 1 up to end of study (up to approx. 3 years)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 mai 2024

Achèvement primaire (Estimé)

14 mars 2029

Achèvement de l'étude (Estimé)

14 mars 2029

Dates d'inscription aux études

Première soumission

10 novembre 2023

Première soumission répondant aux critères de contrôle qualité

10 novembre 2023

Première publication (Réel)

18 novembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Délai de partage IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Critères d'accès au partage IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner